Estimates Revisions Lineage Cell Therapeutics, Inc.
Stocks
LCTX
US53566P1093
Biotechnology & Medical Research
|
Market Closed -
NYSE
06:00:00 24/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 0.9567 USD | -8.01% |
|
-10.59% | -42.71% |
| 07/08 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 | |
| 07/08 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- LCTX Stock
- Consensus Lineage Cell Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
